REGENXBIO Inc. Chief Technology Officer Malzahn Craig forfeited 234 shares at $9.32 per share on September 1, 2026. The transaction matters to investors because his reported ownership afterward stood at 81,960 shares, giving a precise view of his remaining position in the company.
Key Highlights
- The transaction occurred on September 1, 2026.
- Malzahn Craig serves as REGENXBIO Inc.’s Chief Technology Officer.
- His reported ownership after the transaction was 81,960 shares.
REGENXBIO Inc. (NASDAQ: RGNX) recorded the forfeiture of 234 shares at $9.32 per share by Chief Technology Officer Malzahn Craig on September 1, 2026. His reported ownership after the transaction stood at 81,960 shares.
CTO’s Post-Transaction Ownership Stood at 81,960 Shares
Malzahn Craig holds the Chief Technology Officer role at REGENXBIO Inc. The transaction involved 234 shares, with each share valued at $9.32. The stated transaction date was September 1, 2026. That figure reflects his position following the transaction.
FAQs
Q: What happened to Malzahn Craig’s REGENXBIO shares?
A: REGENXBIO Chief Technology Officer Malzahn Craig forfeited 234 shares at $9.32 per share on September 1, 2026. His reported ownership afterward was 81,960 shares.
Q: How many REGENXBIO shares does Malzahn Craig own after the transaction?
A: Malzahn Craig’s reported REGENXBIO ownership following the forfeiture was 81,960 shares. The transaction involved the forfeiture of 234 shares at $9.32 per share.
Q: When did the REGENXBIO share forfeiture occur?
A: The REGENXBIO share forfeiture occurred on September 1, 2026. Malzahn Craig, the company’s Chief Technology Officer, forfeited 234 shares at $9.32 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.